Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes

Circulation Journal

Volumn 72, Issue 8, 2008, Pages 1346-1350

  Yamamuro, Megumi ^a   Yoshimura, Michihiro ^b   Nakayama, Masafumi ^a   Abe, Koji ^a   Sumida, Hitoshi ^a   Sugiyama, Seigo ^a   Saito, Yoshihiko ^c   Nakao, Kazuwa ^d   Yasue, Hirofumi ^e   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e Kumamoto Aging Research Institute   (Japan)

Author keywords

Heart failure; Hormones; Hypertrophy

Indexed keywords

ALDOSTERONE; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; EPLERENONE; MESSENGER RNA; MINERALOCORTICOID RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART MUSCLE CELL; HORMONAL REGULATION; NEWBORN; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; DOWN-REGULATION; MYOCYTES, CARDIAC; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, WISTAR; RECEPTORS, ALDOSTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPIRONOLACTONE; TIME FACTORS;

EID: 48749108107     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.1346     Document Type: Article

References (33)

1. Mizuno Y, Michihiro Y, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103: 72-77.
2. Yamamoto N, Yasue H, Mizuno Y, Yoshimura M, Fujii H, Nakayama M, et al. Aldosterone is produced from the ventricles of patients with essential hypertension. Hypertension 2002; 39: 958-962.
3. Yoshimura M, Nakamura S, Ito T, Nakayama M, Harada E, Mizuno Y, et al. Expression of aldosterone synthase gene in failing human heart: Quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 2002; 87: 3936-3940.
4. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001; 104: 137-139.
5. Donoghue M, Hsieh F, Baronas E, Godbout K, Gossehn M, Staghano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: 1-9.
6. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme; Cloning and functional expression as a captopril-insensitive carhoxypeptidase. J Biol Chem 2000; 275: 33238-33243.
7. Burrell LM, Risvanis 1, Kubota E, Dean RG MacDonald PS, Lu S, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005; 26: 369-375.
8. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828.
9. Bernstein KE. Two ACEs and a heart. Nature 2002; 417: 799-802.
10. Danilczyk U, Eriksson U, Crackower MA, Penninger JM. A story of two ACEs. J Mol Med 2003; 81: 227-234.
11. Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 2003; 13: 93-101.
12. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002; 105: 1548-1550.
13. Ferreira Al, Santos RA, Almeida AP. Angiotensin-(1-7): Cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001; 38: 665-658.
14. Averill DB, Ishiyama Y, Chappell MC, Ferrario CM. Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 2003; 108: 2141-2146.
15. de Gasparo M, loss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, et al. Three new epoxy-spirolactone derivatives; Characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650-656.
16. Yamamuro M, Yoshimura M, Nakayama M, Abe K, Shono M, Suzuki S, et al. Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology 2006; 147: 1314-1321.
17. Ito T, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E, et al. Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation 2003; 107: 807-810.
18. Tikellis C, lohnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392-397.
19. Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor gamma-ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J Biol Chem 2004; 279: 8300-8315.
20. Weber KT. Mechanisms of disease: Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-1697.
21. Vasan RS, Evans JC, Larson MG, Wilson PWF, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in non-hypertensive persons. N Engl J Med 2004; 351: 33-41.
22. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: Role of ETA receptors. Hypertension 2002; 39: 679-684.
23. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EAG, Goellner JJ, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003; 93: 69-76.
24. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl Med 1999; 341: 709-717.
25. Pitt B, Remme W, Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
26. Karram T, Abbasi A, Keidar S, Golomb E, Hochberg I, Winaver J, et al. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol 2005; 289: H1351-H1358.
27. Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 2005; 97: 946-953.
28. Takeda Y, Zhu A, Yoneda T, Usukura M, Takata H, Yamagishi M. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2007; 20: 1119-1124.
29. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al. Myocardial production of aldosterone and corticosterone in the rat. J Biol Chem 1998; 273: 4883-4891.
30. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac pheno-type of hypertrophic cardiomyopathy. Circulation 2004; 109: 1284-1291.
31. Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, Rafestin-Oblin M. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEES Lett 1999; 464: 9-13.
32. Ishiyama Y, GaUagher PE, Averill DB, TaUant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43: 970-976.
33. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111: 2605-2610.